高盛:维持丽珠医药(01513)“中性”评级 目标价降至20.35港元

智通财经网
01 Apr

智通财经APP获悉,高盛发布研报称,丽珠医药(01513)去年第四季销售额同比下跌1.6%,表现疲软符合预期,现有产品组合已达到瓶颈,未来增长潜力将取决于新产品发展,基于最新业绩表现及项目研发进展,将今明两年盈利预测下调7.3%及8.2%。该行将丽珠医药目标价从21.1港元下调至20.35港元,维持“中性”评级。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10